TIL

Instil Bio, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website instilbio.com
Employees(FY) 192
ISIN US45783C2008

Performance

+2.4%

1W

+11.33%

1M

-2.21%

3M

+71.03%

6M

+50.92%

YTD

-4.36%

1Y

Profile

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Advanced Technical Analysis

Technical Analysis of TIL 2024-05-10

Overview:

In analyzing the technical indicators for the last 5 days of TIL stock, we will delve into the trends, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions to guide your in...

See more ...

Recent News & Updates

2024-05-10 01:54
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024(Investorplace)
2024-05-09 19:00
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-03-27 00:00
What Makes Instil Bio (TIL) a New Buy Stock(Zacks)
2024-03-21 10:52
TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023(Investorplace)
2024-03-21 05:00
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update(Globenewswire)
2024-01-17 23:28
Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why(Yahoo Finance)
2024-01-15 19:00
Instil Bio Announces Strategic Update(Globenewswire)
2023-12-12 21:52
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023(Investorplace)
2023-12-12 21:51
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023(Investorplace)
2023-12-05 04:00
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split(Globenewswire)
2023-11-13 04:00
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update(Globenewswire)
2023-11-05 18:00
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting(Globenewswire)
2023-08-30 21:35
After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL)(Yahoo Finance)
2023-08-13 19:00
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update(Yahoo Finance)
2023-06-26 04:38
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference(Yahoo Finance)
2023-05-10 19:00
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update(Yahoo Finance)
2023-03-30 19:00
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update(Yahoo Finance)
2023-03-21 19:57
Heres Why Instil Bio (TIL) Declined in Q4(Yahoo Finance)
2023-02-16 18:04
Private equity firms account for 39% of Instil Bio, Inc.'s (NASDAQ:TIL) ownership, while institutions account for 34%(Yahoo Finance)
2023-01-31 04:00
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site(Yahoo Finance)
2023-01-08 23:30
Instil Bio Resumes ITIL-306 Study In Lung, Ovarian, Renal Cancers(Yahoo Finance)
2023-01-08 18:00
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer(Yahoo Finance)
2022-12-12 20:35
Down 61.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL)(Yahoo Finance)
2022-12-08 20:35
Down 59.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL)(Yahoo Finance)
2022-12-07 22:04
Instil Bio Discontinues ITIL-168 Cancer Trials, Layoffs 60% Of Its Employees(Yahoo Finance)
2022-12-07 18:00
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce(Yahoo Finance)
2022-11-14 03:07
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update(Yahoo Finance)
2022-11-07 18:00
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting(Yahoo Finance)
2022-10-30 22:40
Instil Bio Share Sink After Enrollment Pause In Cancer Therapy Trials(Yahoo Finance)
2022-10-30 20:52
Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials(Marketwatch)

Page 1 of 3

previousnext